Baader Bank Aktiengesellschaft Trims Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Baader Bank Aktiengesellschaft reduced its holdings in Bristol-Myers Squibb (NYSE:BMY) by 26.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,733 shares of the biopharmaceutical company’s stock after selling 1,738 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Bristol-Myers Squibb were worth $268,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Foster & Motley Inc. increased its holdings in Bristol-Myers Squibb by 25.6% in the 4th quarter. Foster & Motley Inc. now owns 32,842 shares of the biopharmaceutical company’s stock worth $1,858,000 after acquiring an additional 6,684 shares in the last quarter. Swedbank AB raised its holdings in shares of Bristol-Myers Squibb by 1.5% during the fourth quarter. Swedbank AB now owns 3,185,674 shares of the biopharmaceutical company’s stock valued at $180,182,000 after acquiring an additional 46,122 shares during the last quarter. Strategic Blueprint LLC boosted its stake in shares of Bristol-Myers Squibb by 4.1% in the fourth quarter. Strategic Blueprint LLC now owns 12,684 shares of the biopharmaceutical company’s stock worth $717,000 after acquiring an additional 502 shares during the last quarter. Asset Dedication LLC raised its stake in Bristol-Myers Squibb by 124.7% in the 4th quarter. Asset Dedication LLC now owns 14,487 shares of the biopharmaceutical company’s stock valued at $819,000 after purchasing an additional 8,041 shares during the last quarter. Finally, R Squared Ltd acquired a new stake in Bristol-Myers Squibb during the 4th quarter worth $40,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Phil M. Holzer sold 700 shares of the company’s stock in a transaction on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This represents a 5.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Price Performance

Shares of BMY opened at $59.11 on Friday. Bristol-Myers Squibb has a 52 week low of $39.35 and a 52 week high of $61.10. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. The firm has a market cap of $119.88 billion, a price-to-earnings ratio of -16.46, a PEG ratio of 2.02 and a beta of 0.45. The stock has a 50 day moving average of $57.59 and a 200-day moving average of $53.02.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. During the same quarter in the previous year, the firm earned $2.00 earnings per share. The firm’s revenue for the quarter was up 8.4% compared to the same quarter last year. As a group, analysts forecast that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. This represents a $2.48 annualized dividend and a yield of 4.20%. Bristol-Myers Squibb’s dividend payout ratio is -69.08%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on BMY shares. Wolfe Research began coverage on shares of Bristol-Myers Squibb in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Truist Financial boosted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, January 8th. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Cantor Fitzgerald restated a “neutral” rating and issued a $50.00 target price on shares of Bristol-Myers Squibb in a research report on Friday, October 18th. Finally, Leerink Partners upgraded Bristol-Myers Squibb from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $55.00 to $73.00 in a report on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $56.60.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.